ENVISTA INTRAOCULAR LENS
Report
- Report Number
- 0001313525-2025-00071
- Event Type
- Injury
- Date Received
- April 23, 2025
- Date of Event
- February 4, 2025
- Report Date
- March 14, 2025
- Manufacturer
- BAUSCH + LOMB
- Product Code
- HQL
- UDI-DI
- 10757770607928
- PMA / PMN Number
- P910056
- Removal / Correction Number
- RES96594
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- OH, US
- Reporter Occupation
- NURSE
- Health Professional
- Yes
Narratives
THE DEVICE REMAINS IMPLANTED. INVESTIGATION OF THIS EVENT IS IN PROGRESS. RECALL OF DEVICE IS UNDERWAY.
IT WAS REPORTED THAT 1 DAY AFTER IMPLANTATION OF AN INTRAOCULAR LENS (IOL) INTO THE RIGHT EYE (OD), THE PATIENT PRESENT WITH BLURRY VISION WITH BEST CORRECTED DISTANCE VISUAL ACUITY DECREASING TO 20/150 PH, THUMBPRINT FLOATER, 0.2MM HYPOPYON W/TEMPORAL FIBRIN, 3-5 + WHITE CELLS, AND ROBUST INFLAMMATORY RESPONSE CONTINUING INTO THE NEXT DAY. ON DAY 3 POST-OP, THE PATIENT COMPLAINED OF LIGHT SENSITIVITY, SEEING A CHECKERED PATTERN, AND WHITE BLOBS WITH BLACK WORMS EVERYWHERE WITH VISUAL ACUITY FURTHER DECREASING. UPON EXAMINATION, THE SURGEON NOTED INCREASED VITREOUS OPACITIES AND RETINAL HEMORRHAGES AND WAS REFERRED FOR A VITREOUS TAP & INJECTIONS OF 1MG VANCOMYCIN, 100MG CEFTAZIDIME, & 0.4MG DEXAMETHASONE WERE ADMINISTERED. RESULTS OF THE CULTURE & SENSITIVITY WERE NEGATIVE. PATIENT OUTCOME IS GOOD. THE FOLLOWING MEDICATIONS WERE PRESCRIBED FOR USE AT HOME POST-OPERATIVELY: MOXIFLOXACIN GTT 0.5% 3X 1 DAY (INCREASED TO AID) TAPER. PREDNISOLONE GTT 1% 3X 1 DAY (INCREASED Q HOUR) TAPER. PROLENSA GTT 0.07% 1 X DAY (INCREASED QID) TAPER. MEDROL PACK 4 MG TAB TAKE AS DIRECTED ON PACK. DUREZOL 0.05% 1 GTT Q HR.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 628742 | ENVISTA INTRAOCULAR LENS | INTRAOCULAR LENS | HQL | BAUSCH + LOMB | EE | 3Q26255 | 10757770607928 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 66 YR | Male | Required Intervention | DUOVISC, ALCON BSS, B+L INJECTOR SYSTEM. |